Clinical trial
Study to Evaluate the Safety and Effectiveness of Zostavax™ in Subjects 50 - 59 Years of Age (V211-022)
Study to Evaluate the Safety and Effectiveness of Zostavax™ in Subjects 50 - 59 Years of Age (V211-022)
This study will look at how well Zostavax™ works in preventing shingles in participants ages 50-59 years old.
Study Type: Interventional (Clinical Trial)
Actual Enrollment: 22439 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: A Phase III Clinical Trial to Evaluate the Efficacy, Immunogenicity, Safety and Tolerability of Zostavax™ in Subjects 50-59 Years of Age
Study Start Date: October 2007
Actual Primary Completion Date: January 2010
Actual Study Completion Date: January 2010
Arm:
- Experimental: Zostavax™
- Placebo Comparator: Placebo
| Category | Value |
|---|---|
| Study type(s) | Interventional |
| Expected enrolment | 22439 |
| Study start date | 01 October 2007 |
| Actual study completion date | 01 January 2010 |